Abstract
INTRODUCTION
Over the past 10 years, the rise in video-assisted thoracic surgery (VATS) for treating early-stage non-small-cell lung carcinoma (NSCLC) has been tremendous. After more than a decade of skepticism, VATS anatomical resections have been mentioned in 2009 as an acceptable alternative to thoracotomy [1, 2] and eventually recommended as the preferable approach for earlystage NSCLC by the American College of Chest Physicians (ACCP) guidelines in 2013 [3] . It is now known that VATS result in decreased postoperative pain, improved immune tolerance measured by cytokine release, reduced pulmonary complications, shorter hospital stay and better compliance to adjuvant chemotherapy [4] . However, many points still require investigation. It is not clear whether the better results of VATS lobectomies are related to the approach itself or to the concomitant changes in patient profiles at high-volume VATS centres [5] . Indeed, biases in the selection of patients do most likely exist, as VATS lobectomies are performed in patients with lower stage tumours and, generally, when a non-complex resection is foreseen [6] . In addition, even though most publications based on clinical or administrative databases suggest a lower postoperative morbidity rate, the question of intraoperative complications remains open, with some studies reporting a significant and worrying rate of major intraoperative complications that do not seem related to the surgical experience but might be inherent to the thoracoscopic approach itself [7, 8] . Finally, the most important question is the effectiveness of this technique in treating lung cancer, which is best evaluated by an analysis of long-term survival.
A meta-analysis of 20 observational studies comparing thoracoscopy to thoracotomy reported the advantage of long-term survival in patients who underwent thoracoscopy [9] . In addition to the selection bias due to their retrospective nature, these studies have 2 weaknesses: the heterogeneity of patients and the lack of details on the technique used (pure thoracoscopic, video assisted or hybrid) and on the type of lymph node (LN) dissection. The results are difficult to analyse as there are different surgical techniques, with some comprising a minithoracotomyso-called hybrid-or an access incision, or no access incision with a full endoscopic approach. The latter has been considered a challenging or even unreasonable access because, as written several years ago by some authors, it might compromise the oncological results [10] .
Since 2007, we have been using a standardized full thoracoscopic approach lobectomy or segmentectomy for clinical Stage I NSCLC [11] . We have reported our results in terms of perioperative outcome, morbidity [8] and quality of LN dissection [12] , but long-term survival data were missing. The aim of this work was to analyse the results of the fully-closed chest technique in terms of nodal upstaging and long-term survival.
MATERIALS AND METHODS

Patients
All patients who were operated on in our institution for NSCLC between January 2007 and August 2016 by a full thoracoscopic technique (FT) were included. Patients operated on after this date were excluded to allow for a minimum follow-up time of 1 year. The analysis was done retrospectively from our database. This database (declared on CNIL1682873v0) is an 'intent to treat' prospective database of all thoracoscopic procedures for major pulmonary resections, including all converted patients. The study was approved by the ethics committee for clinical research of the French Society for Thoracic and Cardiovascular Surgery (CERC-SFCTCV-2015-12-7-51-14-Lujo).
The database included clinical and pathological variables, type of resection, intraoperative and postoperative data, complications, recurrence and survival. The preoperative staging was based on a routine computed tomography (CT) scan, brain magnetic resonance imaging or a cerebral CT scan and a fluorodeoxyglucose positron emission tomography scan (PET scan). For patients with abnormal mediastinal and/or hilar LNs at CT and/or PET, endobronchial ultrasound (EBUS) was performed for mediastinal and hilar staging. In case of negative EBUS and a highly suspicious malignant LN, mediastinoscopy was performed. Postoperative staging was done using the 7th edition of the tumour, nodes and metastasis (TNM) classification. Overall survival (OS) was defined as the time between surgery and deathwhatever the cause-or date of the last follow-up. Disease-free survival (DFS) corresponded to the time from surgery to tumour recurrence (local, metastatic or metachronous NSCLC) or death. Tumour-specific survival (TSS) corresponded to the time from surgery to lung-cancer-related death. In-hospital mortality was defined as death within 30 days after the operation or in-hospital death without discharge.
Operative technique
Lobectomies and segmentectomies were performed by all 4 surgeons of our department using the same standardized technique with pure monitor display, high-definition imaging system and a 10-mm deflectable endoscope hold on a scope positioner, 3-4 ports without utility incision (an incision was made at the completion of the resection, its length being suited to the size of the specimen) and specifically designed small-diameter instruments. Compared to the so-called 'anterior' approach that comprises a dissection of the hilum with a fissure last division, our technique can be compared to the 'posterior' approach described by Walker et al. [13] , which should rather be named 'fissure-based' or 'fissure-first' with dissection of the pulmonary artery branches in the fissure. The lobectomy or segmentectomy was completed with a radical hilar and mediastinal LN dissection, according to a previously reported technique [12] . In summary, Stations 2, 4 and 7-10 on the right side and Stations 5-10 on the left side were totally removed. All peribronchial (Station 11) and interlobar and intersegmental (Stations 12 and 13) were cleared. During segmentectomies, intersegmental LNs and safety margins were examined by a frozen section. The procedure was converted to lobectomy in case of invaded LN or insufficient safety margin. Although LN dissection was radical in most patients, it was only partial or even not performed in patients older than 80 years when adjuvant chemotherapy would have been unfeasible, regardless of the postoperative stage.
Anatomical sublobar resections (SLRs), i.e. segmentectomies, were performed in cT1a and in some cT1b tumours for patients who had undergone a previous major pulmonary resection and/or whose pulmonary function was poor and/or who presented with 2 synchronous or metachronous tumours. The chest tube was removed if daily output was inferior to 400 ml with no air leakage.
Statistical analysis
Statistical analysis was performed using the IBM SPSS software version 25 for windows. Variables are expressed as median with lower and upper quartiles and categorical variables as absolute and relative frequencies. Analysis of follow-up data was done using the KaplanMeier method, and groups were compared with the log-rank test. Primary outcome was survival expressed as mean and 95% confidence interval. We also performed univariable and multivariable Cox regression analyses on OS and TSS. Univariable models were fitted to all potential predictors, and those with a P-value <0.2 were included in a multivariable model. The proportional hazard assumption was checked with log-log plots.
RESULTS
Demographics
At the time of writing this article, 1217 FT major pulmonary resections-regardless of the indication-were performed in our department ( Table 1 ). The present study is based on a total of 648 patients presenting with proven or suspected NSCLC who were operated on by an FT between January 2007 and August 2016. Sixteen oligometastatic Stage IV patients (13 brains, 2 adrenals and 1 pleural metastasis) were excluded. Among the remaining 632 patients, 465 had clinical Stage IA and 156 clinical Stage IB tumours. Eleven patients had a higher staging because of separate nodule in the same lobe (n = 6), separate nodule in an ipsilateral lobe (n = 1) or tumour size >5 cm (n = 4). FT was, however, decided in these patients because there was no nodal involvement on a PET scan.
Perioperative results
The median operating time was 160 min (125-200 min), and the median estimated blood loss was 100 ml (50-150 ml) ( Table 2 ). There were 40 conversions to thoracotomy (6.33%) for vascular tears (n = 15), oncological (n = 2) or technical issues such as dense adherences, or a totally fused fissure (n = 23). Thirty-day or in-hospital mortality was 0.95%: 1 intraoperative death due to cardiac injury already reported [8] , 3 acute respiratory distress syndromes, 1 secondary rupture of the spleen and 1 massive pulmonary embolism. Complications occurred in 185 patients (29.3%). Most frequent complications were prolonged air leak (n = 59), atrial fibrillation (n = 23) and pneumonia (n = 22). Chest tube duration was 3 days (2-5 days), and length of stay was 6 days (5-8 days).
Pathological analysis
Adenocarcinoma was the most frequent histological type (n = 498, 78.8%) ( Table 3) . Four hundred and eighty-one patients (77.8%) were in Stage I on pathological examination, whereas 140 patients (22.5%) were upstaged ( Table 4 ). The reasons for T-upstaging (n = 51) were the discovery of a second tumour in the same lobe or in an ipsilateral lobe, invasion of the parietal pleura and underestimation of tumour size on a preoperative CT scan. The rate of pT3 upstaging is likely to be overestimated as some of the patients had a doubtful additional small nodule in the same lobe on a preoperative CT scan. Nodal upstaging to N1 (n = 49) or N2 (n = 49) was observed in 98 (15.8%) of clinical Stage I patients. Sixty-two (63.3%) of these patients received adjuvant chemotherapy. The main reason for not administrating adjuvant treatment was age > 80 years. Nine patients had combined T and N upstaging.
Survival
The mean follow-up was 34.5 months. Five-year OS of the whole cohort was 75% (95% confidence interval 69.9-80.1%) and TSS (Table 5 ). In the Cox analysis for TSS, the pathological stage and the type of resection were significant. With progressive change in our patients' profile, the proportion of SLRs rose from 8% in 2007-2008 to 37 .6% in 2016. Fig. 2A shows the survival curve (OS and TSS) for lobectomy versus segmentectomy in patients with tumours < _ 2 cm, for which segmentectomy was intended. The difference in OS was not statistically different (P = 0.634, 78.9%, 70.5-87.3% vs 74.2%, 58.3-90.1%). However, the groups are not matched, and there is a tumour size difference between the groups: 1.7 cm (1.5-2 cm) in the lobectomy group and 1.5 cm (1.2-1.8 cm, P < 0.001) in the segmentectomy group. Nodal upstaging (N1: 17 vs 1, N2: 12 vs 6, P = 0.024) and number of LNs resected (19 vs 14, P < 0.001) were significantly higher in lobectomy than in segmentectomy. This had no impact on OS as seen in Fig. 2B . On the other hand, a subgroup of patients (n = 33) had no systematic radical lymphadenectomy. This group was significantly older [77 years (62-83 years) vs 65 years (59-71 years), P < 0.001] and had a higher percentage of SLR (n = 15, 45.5% vs n = 145, 24.2%, P = 0.006). Excluding this subgroup from the analysis had no significant impact on 5-year OS (75.3% vs 75.%), and we decided to keep them included to reflect the results of our clinical practice.
DISCUSSION
Acceptance of a thoracoscopic approach for major pulmonary resections took time, mainly because of doubts about its oncological validity. However, over the recent years, a rise in the use of VATS has been observed, and the ACCP guidelines now recommend the VATS approach for Stage I NSCLC [3] . As recently stressed by Treasure [14] , surgeons performing VATS lobectomy want to reach multiples goals: safety, efficacy and oncological effectiveness measured by OS and DFS. We will use this framework to comment our results.
Safety
Establishing a VATS lobectomy programme means a steep learning curve, and even specialized centres cannot avoid major intraoperative and postoperative complications, as reported by the survey of the European Society of Thoracic Surgeons [7] .
Nevertheless, most studies report comparable or better perioperative morbidity and mortality with VATS lobectomy compared to the open approach, which was even more pronounced in high-volume centres [5] . Similar conclusions are reached when focusing on VATS resections for lung cancer, with a significant reduction in the length of stay in high-volume centres [5] .
Efficacy
Efficacy is defined as 'whether the technique achieves the initial intention of the treatment which is to remove the lobe or the segment successfully' [14] . The full thoracoscopic approach did not seem to result in an oncological compromise. Planned segmentectomy were extended to lobectomy if intersegmental LNs were positive at 'frozen section examination' and/or if the safety margin was not sufficient [15] . If the principles of an oncological resection could not be matched [16] , thoracoscopy was converted to thoracotomy. Finally, all patients had the initially planned surgery (lobectomy/segmentectomy) or-in the segmentectomy group-a more extensive resection (adjacent segmentectomy of lobectomy) if needed [15] . In the group of patients who underwent a more extensive resection than initially planned, there was no conversion.
Oncological effectiveness
Oncological effectiveness refers to whether VATS major pulmonary resection achieves similar oncological results as conventional thoracotomy. In lung cancer surgery, resections must be performed according to the oncological principles defined by the International Association for the Study of Lung Cancer (IASLC): free resection margins proved microscopically, systematic nodal dissection or lobe-specific systematic nodal dissection, no extracapsular nodal extension of the tumour and the highest mediastinal node removed must be negative [16] . Effectiveness can only be definitively evaluated by the study of DFS and long-term survival. As setting randomized trials comparing different approaches and using such criteria appear unrealistic, evaluating the fulfilment of the aforementioned resection criteria can be achieved by studying and comparing OS and DFS of a large series. Analysing these parameters in our intention-to-treat VATS series was the main reason of this study. In a published series, long-term survival after VATS lobectomy for NSCLC ranges from 63.6% to 97% ( 
Does the technique influence long-term outcome?
There is no precise standard technique for VATS lobectomy, and the favoured surgical approach varies dramatically among surgeons. Dissections can begin in the fissure or in the hilum (anterior to posterior). In our department, all operations were performed according to a previously reported technique based on a full thoracoscopic and fissure-first approach [12] . The reason for favouring this approach was to allow an extensive dissection of LNs in the fissure with a frozen section if needed, to detect variations of vascular anatomy and to dissect and clear the origin of the lobar or segmental bronchus. Recently, Samejima et al. [21] have demonstrated that a fissure-first approach does not increase the prevalence of air leaks, operating time and duration of chest drainage, while enabling a better LN dissection. This approach has been criticized for being challenging and more stressful in case of vascular injury and conversion because of the lack of utility incision. However, these criticisms do not seem to be supported by the operative time, intraoperative blood loss, conversions and complications rates and eventually by the long-term survival [9] . Our upstaging rate of 22.5% could be split into T-upstaging (8.2%), which was mainly explained by the discovery of a second tumour in the same lobe and an N-upstaging of 15.8%. An FT enables LN dissection as complete as through a thoracotomy, as demonstrated by our team [12] . This is made possible, thanks to the use of a deflectable endoscope that provides a bird's eye view on all LN stations and several instruments that facilitate exposure and LN grasping. In our series, the final rate of nodal upstaging in clinical Stage I patients was 7.9% for N1 and 7.9% for N2. This is comparable to the rates obtained by thoracotomy in our department [12] and higher than the 3.6% reported by Khullar et al. [22] for the VATS approach or the 11.9% reported by Medbery et al. [23] for open approach. However, there is still an ongoing debate on the efficacy of VATS lymphadenectomy. Results of the American College of Surgery Oncology Group Z0030 Trial showed no difference in the number of LNs removed by VATS compared with open thoracotomy, but conclusions of other studies vary. Boffa et al. [24] reported that N1 upstaging was significantly lower in the VATS group than in the thoracotomy group. This difference disappeared as experience increased.
Segmentectomies
A substantial proportion of the patients had an anatomical SLR. The main indications were metachronous or synchronous NSCLC in patients with poor lung function and/or major comorbidities. However, oncological results of SLR are still a matter of debate.
Whitson et al. [25] analysed the survival of 14 473 patients who underwent either lobectomy or SLR for Stage I NSCLCs from the Surveillance Epidemiology and End Results (SEER ) database. They demonstrated that lobectomy had a significantly better survival, even for tumours less than 2.1 cm in diameter. However, in such a multicentric analysis, information on technical details and on intraoperative study of resection margins and intersegmental LNs is unavailable. Most likely, some SLR patients were understaged, which might explain a pejoration of survival. If all patients had an intraoperative examination of an LN and of the resection margins, some would be converted into lobectomy, and the results could be more adequately compared [16] .
Compared to lobectomies, SLRs comprise an increased risk of local recurrence as resection margins tend to be closer to the tumour. Schuchert et al. [26] demonstrated that outcomes of segmentectomies compare favourably with lobectomy for Stage I NSCLC but that margin/tumour ratios of less than 1 are associated with a higher rate of recurrence. As suggested by other authors [27] , we routinely use a modelling software before SLR, which comprises a virtual safety margin that helps the decision-making and the planning of an adequate resection.
Finally, intersegmental LN clearance appears to be of major importance during thoracoscopic segmentectomies [25, 28] . Wolf et al. [28] have demonstrated in patients with small-sized NSCLCs that local recurrence rate and OS and recurrence-free survival distributions were similar between segmentectomy and lobectomy when LNs were sampled during segmentectomy. Although an intraoperative frozen section is time-consuming, systematic examination of Stations 10-12 LNs and resection margin measurement were performed in the present study, which may explain the similar 5-year OS and DFS between the segmentectomy and lobectomy groups in our series. Okada et al. [29] also reported that long-term survival was equivalent for segmentectomy and lobectomy in patients with Stage IA adenocarcinomas. Similarly, Cao et al. [30] demonstrated in a large meta-analysis that patients intentionally treated by an SLR for an early-stage peripheral NSCLC had OS and DFS that were not significantly different from those treated by lobectomy. They also showed that the lower OS in the 'compromised group' of patients who underwent segmentectomies due to medical comorbidities or cardiopulmonary limitations were probably explained by noncancer-related deaths in these fragile patients rather than the oncological inferiority of SLR (30) .
CONCLUSION
Despite the lack of randomized studies comparing thoracoscopy and thoracotomy, it is now known, based on large cohort studies, that the early outcome of major pulmonary resection is more favourable when performed by thoracoscopy. There is also a growing body of evidence that long-term survival is not compromised by a video-assisted or thoracoscopic approach. This study adds the results of a full-closed-chest technique and shows that a utility incision is not a condition for achieving satisfactory oncological results in terms of nodal upstaging and survival.
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